Tubulis generates antibody-drug conjugates with unique properties for solid tumor indications.
Tubulis has raised $400.6M in total funding. The most recent round was Series C. The last funding was announced in October 2025.
Tubulis's investors include Wellington Management, HTGF (High-Tech Gruenderfonds), Seventure Partners, EQT Life Sciences, Andera Partners.
Tubulis is headquartered in Munich, Germany.
Tubulis generates antibody-drug conjugates with unique properties for solid tumor indications.
Tubulis is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tubulis — Funding & Investors." VCBacked, October 15, 2025, https://www.vcbacked.co/company/tubulis. Accessed July 19, 2026.
VCBacked. (2025). Tubulis — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/tubulis
{{cite web |title=Tubulis — Funding & Investors |url=https://www.vcbacked.co/company/tubulis |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated